Zenas BioPharma, Inc., was originally incorporated in Cayman on November 12, 2019 under the name Zenas BioPharma (Cayman) Limited. On August 2, 2023, the company was incorporated in Delaware and simultaneously changed its name from Zenas BioPharma (Cayman) Limited to Zenas BioPharma, Inc. The company is a clinical-stage global biopharmaceutical company dedicated to the development and commercialization of immune-based transformative therapies for patients in need. With the growing understanding of the pathogenesis of autoimmune diseases and the expansion of promising immunology-based pharmacological targets, they are building a biopharmaceutical company focused on immunology and inflammation (" I & I ").